



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Datasheet for 000-001-M48**HIV tat 47-57, Cys****Overview**

Description:	HIV-1 tat, (47-57) peptide - 000-001-M48
Item No.:	000-001-M48
Size:	1 mg
Origin:	HIV-1

Product Details

Background: Translocation through the plasma membrane has been shown to be a major limiting step for the delivery of various macromolecules to the cytoplasm and other intracellular compartments (e.g., mitochondria, nucleus). Numerous studies have confirmed that specific peptide sequences known as cell penetrating peptides (CPP) derived from proteins able to cross the plasma membrane, can be added to various cargo and delivered across cell membranes. The cargo molecules that have been successfully transported into cells includes oligonucleotides, peptides, peptide nucleic acids, proteins and nanoparticles. One of these translocating peptides was derived from the HIV-1 Tat protein, specifically located within the first exon of the HIV tat protein. The specific HIV tat sequence is highly basic (cationic) and is readily added to peptides either as a preformed peptide with a site for direct conjugation to other molecules (typically a cysteine). Addition of the tat-cargo complex (5-50 uM concentration) to cells for 30-60 minutes results in the transfer of the tat-cargo complex to intracellular locations in a rapid, dose-dependent manner. The addition of nuclear or mitochondrial localization sequences has been shown to specifically direct the cargo to the nucleus or mitochondria respectively.

Synonyms:	Protein Tat, Transactivating regulatory protein, Human immunodeficiency virus type 1 (HIV-1), control peptide, blocking peptide
Species of Origin:	HIV-1
Type:	Peptide

Target Details

Purity/Specificity: Greater than 95% specific peptide.

Application Details

Application Note:	HIV-1 tat, 47-57 Control Peptide is suitable for use in ELISA, Western Blot, Dot blot, PCA, and other assays. Control peptide should be used at 1.0 µg per 1.0 µl of antiserum in per assay. Specific conditions for reactivity should be optimized by the end user.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

Formulation

Physical State:	Lyophilized
Concentration:	1 mg/mL by dry weight
Buffer:	None
Preservative:	None
Stabilizer:	None
Reconstitution Volume:	1.0 mL
Reconstitution Buffer:	Restore with deionized water (or equivalent)

Shipping & Handling

Shipping Condition:	Ambient
Storage Condition:	Store vial at 2 - 8 ° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

